Top

Published in:

01-04-2012 | Research

Effect of shRNA Mediated Down-Regulation of Annexin A2 on Biological Behavior of Human Lung Adencarcinoma Cells A549

Authors: Yue-xiang Wang, Hui Lv, Ze-xia Li, Cui Li, Xiao-ying Wu

Published in: Pathology & Oncology Research | Issue 2/2012

Abstract

In the previous study, we found that Annexin A2 was significantly up-regulated in lung cancer and could induce related-antigen in lung cancer patients’ serum. To further study the function of Annexin A2, the short hairpin RNA plasmid targeting Annexin A2 was constructed in vitro and transfected into human lung adencarcinoma A549 cells. Knocking down Annexin A2 expression by shRNA, the mRNA level of Annexin A2 was investigated by semi-quantitative RT-PCR. The expression of Annexin A2 protein was examined by Western Blotting and Immuocytochemistry. MTT assay and Transwell chamber model were used to evaluate proliferation and invasion of A549 cells in vitro. The concentration of matrix metalloproteinase-2 (MMP-2) and cathepsin B (CB) in the supernatant was evaluated by ELISA. At 48 h after transfection, the expression of Annexin A2 mRNA and protein was down-regulated significantly, respectively (p < 0.05).The proliferation and invasion capability of A549 cells also decreased significantly (p < 0.05). The concentration of MMP-2 and CB was down-regulated obviously, respectively (p < 0.05). This study implies that Annexin A2 might play an important role in the progression and invasion of human lung cancer cells, and could promote progression of lung cancer by regulating the expression of MMP-2 and CB.

Zeuschner D, Stoorvogel W, Gerke V (2001) Association of annexin 2 with recycling endosomes requires either calcium- or cholesterol-stabilized membrane domains. Eur J Cell Biol 80(8):499–507PubMedCrossRef

Falsey RR, Marron MT, Gunaherath GM, Shirahatti N, Mahadevan D, Gunatilaka AA (2006) Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2:33–38PubMedCrossRef

Mayran N, Parton RG, Gruenberg J (2003) Annexin II regulates multivesicular endosome biogenesis in the degradation pathway of animal cells. EMBO J 22:3242–3253PubMedCrossRef

Knop M, Aareskjold E, Bode G, Gekre V (2004) Rab3D and annexin A2 play a role in regulated secretion of vWF, but not tPA, from endothelial cell. EMBO J 23:2982–2992PubMedCrossRef

Yuan Y-W, Sun A-M, Lui Y, Chen H-L, Banerjee AG (2007) Rna interference of annexin II gene in PC3 cells by using small interference RNA synthesized with in vitro transcription. Chinese Academy of Medical Sciences 22(1):33–37

Gladwin MT, Yao XL, Cowan M, Huang XL, Schneider R, Grant LR (2000) Retinoic acid reduces p11 protein levels in bronchial epithelial cells by a posttranslational mechanism. Am J Physiol Lung Cell Mol Physiol 279(6):1103–1109

Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M (2001) Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21(2B):1339–1345PubMed

Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T (2001) Annexin II over-expression correlates with stromal tenascin-C over-expression: a prognostic marker in colorectal carcinoma. Cancer 92:1419–1426PubMedCrossRef

Ito Y, Arai K, Nozawa R, Yoshida H, Higashiyama T, Takamura Y (2007) S100A10 expression in thyroid neoplasmsoriginating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res 27(4C):2679–2683PubMed

10.

Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T (2007) Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci 98(1):77–82PubMedCrossRef

11.

Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S (2006) Tenascin C and annexin 2 expression in the process of pancreatic carcinogenesis. J Pathol 208:673–685PubMedCrossRef

12.

Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81(2):146–156PubMedCrossRef

13.

Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA (1992) Developmental regulation of annexin II (lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 52:6871–6876PubMed

14.

Syed SP, Martin AM, Haupt HM, Arenas-Elliot CP, Brooks JJ (2007) Angiostatin receptor annexin 2 in vascular tumors including angiosarcoma. Hum Pathol 38:508–513PubMedCrossRef

15.

Yang F, Xiao ZQ, Zhang XZ, Li C, Zhang PF, Li MY (2007) Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 6(2):751–758PubMedCrossRef

16.

Wu XY, Xiao ZQ, Chen ZC, Li C, Li JP, Feng XP et al (2004) Differential analysis of two-dimension gel electrophoresis profiles from the normal-metaplasia-dysplasia-carcinoma tissue of human bronchial epithelium. Pathol Int 54(10):765–773PubMedCrossRef

17.

Li C, Chen ZC, Xiao ZQ, Wu X, Zhan X, Zhang X (2003) Comparative proteomics analysis of human lung squmous carcinoma. Biochem Biophys Res Commun 309(1):253–260PubMedCrossRef

18.

Yuan YW, Sun AM, Lui Y, Chen LH, Banerjee AG (2007) RNA interference of Annexin II gene in PC3 cells by using small interference RNA synthesized with in vitro transcription. Chin Med Sci J 22(1):33–37PubMed

19.

Choi S, Kobayashi M, Wang J, Habelhah H, Okada F, Hamada J (2000) Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with adriamycin. Clin Exp Metastasis 18:45–50PubMedCrossRef

20.

Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I (2005) Metastasis-associated protein S100A4 induces angiogenesis through interaction with annexin II and accelerated plasmin formation. J Biol Chem 280:20833–20841PubMedCrossRef

21.

Musholt TJ, Hanack J, Brehm C, von Wasielewski R, Musholt PB (2005) Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J Surg 29(4):472–482PubMedCrossRef

22.

Frohlich M, Motte P, Galvin K, Takahashi H, Wands J, Ozturk M (1990) Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma. J Mol Cell Biol 10(6):3216–3223

23.

Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, Kim CK et al (2005) Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol 99(1):26–35PubMedCrossRef

24.

Yoon SO, Park SJ, Yun CH, Chung AS (2003) Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36:128–137PubMedCrossRef

25.

Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781–792PubMed

26.

Mai J, Finley RL Jr, Waisman DM, Sloane BF (2000) Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem 275(17):12806–12812PubMedCrossRef

27.

Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH (2007) RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Onool 31(5):1039

28.

Nakajima M, Welch DR, Belloni PN, Nicolson GL (1987) Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 47:4869–4876PubMed

29.

Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P (1990) Limacher JM.A novel metalloproteinases gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699–704PubMedCrossRef

30.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed

31.

Robinson CM, Stone AM, Shields JD, Huntley S, Paterson IC, Prime SS (2003) Functional significance of MMP-2 and MMP-9 expression by human malignant oral keratinocyte cell lines. Arch Oral Biol 48(11):779–786PubMedCrossRef

32.

Podgoraki I, Sloane BF (2003) Cathposin B and its role in cancer progression. Bioehem Symp 70(22):263–276

33.

Rodby S, Sloane BF, Bloin K (2003) PeficeHular cathepsin B and malignant progression. Cancer Metastasis Rev 22(23):271–286

Title: Effect of shRNA Mediated Down-Regulation of Annexin A2 on Biological Behavior of Human Lung Adencarcinoma Cells A549
Authors: Yue-xiang Wang
Hui Lv
Ze-xia Li
Cui Li
Xiao-ying Wu
Publication date: 01-04-2012
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9427-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Prognostic Value of Raf Kinase Inhibitor Protein in Esophageal Squamous Cell Carcinoma

Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer

CDH13 and FLBN3 Gene Methylation are Associated with Poor Prognosis in Colorectal Cancer

p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naïve Prostate Cancer

Amplification of Thymosin Beta 10 and AKAP13 Genes in Metastatic and Aggressive Papillary Thyroid Carcinomas

Anti-Tumour and Anti-Oxidative Potential of Diosgenin against 7, 12-Dimethylbenz(a)anthracene Induced Experimental Oral Carcinogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer